Competitor Analysis: Antiviral Antibodies

The Competitive Intelligence Report Antiviral Antibodies as of July 2008 provides a competitor analysis in the development pipeline of novel antibodies against viral infections such as hepatitis C virus (HCV), hepatitis B virus, SARS coronavirus, respiratory syncytial virus (RSV), human immunedeficiency virus (HIV), influenza, rabies, smallpox and West Nile virus. Among the companies active in the field are mostly biotech companies. The report includes a compilation of current active projects in research and development of novel Antiviral Antibodies. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Additional Information

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.